No significant interaction was observed between piperacillin/tazobactam administration and Aspergillus GM and BDG assays. Positive results for these tests should be evaluated cautiously in patients at high risk for IFI receiving piperacillin/tazobactam.

No abstract

The purpose of this study was to investigate the interaction between intravenous ampicillin-sulbactam treatment and (1,3)-beta-D-glucan (BDG) assay. Fifteen patients with a median age of 60 (16-81) without known risk factors for invasive fungal infections who received a daily dose of 3×2g ampicillin-sulbactam monotherapy from different batches were included in the study. Thirteen patients had soft tissue infections. The 5 of 13 patients who went under surgery had surgical dressings. Serum samples were obtained both before and after antibiotic infusion on the first, third, seventh and tenth days of an ampicillin-sulbactam treatment course. BDG was assayed using the Fungitell kit (Associates of Cape Cod, East Falmouth, MA, USA) according to manufacturers' specifications. All serum samples were also tested for galactomannan (GM) antigenemia by Platelia Aspergillus ELISA (Bio-Rad Laboratories, Marnes-la-Coquette, France). A total of 37 of 117 serum samples were positive for BDG at a threshold of 80pg ml(-1) . Seven of 37 BDG positive serum samples had a GM index ≥0.5. When a cutoff value of ≥0.5 was used for GM positivity, 16 (13.3%) serum samples were positive. For a cutoff value of ≥0.7, eight (6.6%) serum samples were positive. There were no statistically significant differences in the median BDG levels (P=0.47) or median GM indices (P =0.28) of the various sampling times. None of the SAM vials tested positive for BDG or GM. After ruling out fungal infections and all known potential causes of false BDG positivity, environmental contamination remained possible cause of BDG reactivity. We did not observe any significant association of ampicillin-sulbactam administration and positive assays for BDG or GM.

No abstract

AbstractThe purpose of this study was to describe the demographic and clinical features of hospitalized patients with the pandemic H1N1 influenza A virus infection in a tertiary care hospital in Central Anatolia, Turkey. The patients, all over 16 years of age and hospitalized for influenza-like symptoms between 1 November 2009 and 31 December 2009, were retrospectively identified from the records of the Infectious Diseases Department. Eighty patients whose diagnoses were confirmed by real-time PCR were included in this study. The median age of the patients was 27 years; 41 of them were male. Thirty-seven of the patients had a radiologically proven pneumonia. Eighteen of 37 (48.6%) patients with pneumonia had an underlying co-morbid medical condition, and 14 required intensive care unit admission. Patients with pneumonia had higher levels of C-reactive protein. All patients but one received oseltamivir treatment. Six patients with pneumonia received only antiviral therapy, while 31 of the patients with pneumonia received concomitant antibiotic therapy. Three patients who required mechanical ventilatory support died due to respiratory insufficinency. Although our study implicates the later periods of the pandemic, there were no significant differences for patients’ characteristics between our study and previous reports from the countries where the pandemic first occurred.